July 29, 2010Open Access
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Philip W. Kantoff
Rutgers, The State University of New Jersey
C
Celestia S. Higano
Université Paris-Sud
N
Neal D. Shore
Carolina Urologic Research Center
Journals
New England Journal of Medicine
Actions
Institutions
Harvard University
University of Washington
University of California, San Francisco
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...